Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Stool DNA
100%
Gastrointestinal Cancer
100%
DNA Methylation (DNAm)
100%
Cancer Detection
100%
Binding Site Prediction
83%
Differentially Methylated Regions
66%
Stool
60%
Novel Assay
30%
Prediction Accuracy
30%
Pancreatic Cancer
30%
Adenocarcinoma
21%
Cancer Patients
15%
Molecular Test
15%
Cohort Validation
15%
Stage Rates
15%
Primary Tumor Location
15%
Stool DNA Test
15%
2-stage
15%
Gastrointestinal Malignancies
15%
Cancer Control
15%
Pancreaticobiliary Cancer
15%
Condition Selection
15%
Cancer Mortality
15%
Specific Detectivity
15%
Staged Analysis
15%
Next-generation Sequencing
15%
Effective Screening
15%
Gastrointestinal Diseases
15%
Nonmalignant
15%
Cure Rate
15%
Assay Conditions
15%
Confirmatory Study
15%
Stool Specimen
15%
Marker-assisted Selection
15%
Colorectal Cancer Screening
15%
Sensitivity Prediction
15%
Early Detection
15%
Patient Demographics
15%
Cursor
15%
Assay Platforms
15%
FDA-approved Drugs
15%
Assay Technology
15%
Early Cancer
15%
Specific Aims
15%
Potential Impact
15%
Screening Test
8%
Multi-target Stool DNA
8%
Region Specificity
8%
Validation Phase
8%
Foreach
8%
Control Tissue
8%
Ductal Adenocarcinoma
8%
Gastrointestinal Tract
8%
Cancer Screening
6%
Overall Cancer
6%
Small Bowel Adenocarcinoma
6%
Multitarget Stool DNA Test
6%
Gastrointestinal Cancer Screening
6%
Filtering Criteria
6%
Improved Outcomes
6%
Medicine and Dentistry
DNA Methylation
100%
Cancer Diagnosis
100%
Gastrointestinal Cancer
100%
Cancer
63%
Pancreas Cancer
46%
Adenocarcinoma
46%
Health Care Cost
46%
Malignant Neoplasm
36%
Bile Duct Cancer
23%
Cancer Control
23%
Next Generation Sequencing
23%
Gastrointestinal Disease
23%
Case-Control Study
23%
Primary Tumor
23%
Cancer Localization
23%
Cancer Staging
23%
Cancer Mortality
23%
Screening Test
23%
Precursor
23%
Cross-Validation
16%
Cancer Screening
6%
Gastrointestinal Carcinoma
6%
Prevalence
6%
Biochemistry, Genetics and Molecular Biology
DNA Methylation
100%
Differentially Methylated Regions
66%
Cancer Mortality
41%
Next Generation Sequencing
41%
Screening Test
41%
Case-Control Study
41%
Precursor
41%
Cancer Staging
41%
Prevalence
33%
Cancer Screening
33%